vs
Apellis Pharmaceuticals, Inc.（APLS）与Hudson Pacific Properties, Inc.（HPP）财务数据对比。点击上方公司名可切换其他公司
Hudson Pacific Properties, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$256.0M vs $199.9M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -109.4%，领先79.9%），Hudson Pacific Properties, Inc.同比增速更快（22.1% vs -5.9%），过去两年Hudson Pacific Properties, Inc.的营收复合增速更高（9.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
哈德逊太平洋地产是一家房地产投资信托企业，持有1580万平方英尺办公楼、150万平方英尺摄影棚，同时拥有300万平方英尺商用物业的未开发权益，资产布局覆盖美国西海岸及温哥华，注册地位于马里兰州，总部设在洛杉矶，是洛杉矶当地规模最大的独立摄影棚运营商。
APLS vs HPP — 直观对比
营收规模更大
HPP
是对方的1.3倍
$199.9M
营收增速更快
HPP
高出28.0%
-5.9%
净利率更高
APLS
高出79.9%
-109.4%
两年增速更快
HPP
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $256.0M |
| 净利润 | $-59.0M | $-280.2M |
| 毛利率 | — | 60.0% |
| 营业利润率 | -25.6% | -109.8% |
| 净利率 | -29.5% | -109.4% |
| 营收同比 | -5.9% | 22.1% |
| 净利润同比 | -62.2% | -61.5% |
| 每股收益（稀释后） | $-0.40 | $-11.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHPP
| Q4 25 | $199.9M | $256.0M | ||
| Q3 25 | $458.6M | $186.6M | ||
| Q2 25 | $178.5M | $190.0M | ||
| Q1 25 | $166.8M | $198.5M | ||
| Q4 24 | $212.5M | $209.7M | ||
| Q3 24 | $196.8M | $200.4M | ||
| Q2 24 | $199.7M | $218.0M | ||
| Q1 24 | $172.3M | $214.0M |
净利润APLSHPP
| Q4 25 | $-59.0M | $-280.2M | ||
| Q3 25 | $215.7M | $-144.1M | ||
| Q2 25 | $-42.2M | $-87.8M | ||
| Q1 25 | $-92.2M | $-80.3M | ||
| Q4 24 | $-36.4M | $-173.5M | ||
| Q3 24 | $-57.4M | $-107.0M | ||
| Q2 24 | $-37.7M | $-47.6M | ||
| Q1 24 | $-66.4M | $-53.4M |
毛利率APLSHPP
| Q4 25 | — | 60.0% | ||
| Q3 25 | — | 44.3% | ||
| Q2 25 | — | 43.1% | ||
| Q1 25 | — | 42.9% | ||
| Q4 24 | — | 44.7% | ||
| Q3 24 | — | 42.7% | ||
| Q2 24 | — | 48.0% | ||
| Q1 24 | — | 48.6% |
营业利润率APLSHPP
| Q4 25 | -25.6% | -109.8% | ||
| Q3 25 | 48.7% | -77.2% | ||
| Q2 25 | -18.6% | -46.0% | ||
| Q1 25 | -50.0% | -40.4% | ||
| Q4 24 | -12.3% | -83.2% | ||
| Q3 24 | -24.0% | -52.3% | ||
| Q2 24 | -14.7% | -21.6% | ||
| Q1 24 | -36.0% | -24.9% |
净利率APLSHPP
| Q4 25 | -29.5% | -109.4% | ||
| Q3 25 | 47.0% | -77.2% | ||
| Q2 25 | -23.6% | -46.2% | ||
| Q1 25 | -55.3% | -40.5% | ||
| Q4 24 | -17.1% | -82.7% | ||
| Q3 24 | -29.2% | -53.4% | ||
| Q2 24 | -18.9% | -21.8% | ||
| Q1 24 | -38.5% | -24.9% |
每股收益（稀释后）APLSHPP
| Q4 25 | $-0.40 | $-11.57 | ||
| Q3 25 | $1.67 | $-0.30 | ||
| Q2 25 | $-0.33 | $-0.41 | ||
| Q1 25 | $-0.74 | $-0.53 | ||
| Q4 24 | $-0.30 | $-1.19 | ||
| Q3 24 | $-0.46 | $-0.69 | ||
| Q2 24 | $-0.30 | $-0.33 | ||
| Q1 24 | $-0.54 | $-0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $138.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $3.0B |
| 总资产 | $1.1B | $7.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSHPP
| Q4 25 | $466.2M | $138.4M | ||
| Q3 25 | $479.2M | $190.4M | ||
| Q2 25 | $370.0M | $236.0M | ||
| Q1 25 | $358.4M | $86.5M | ||
| Q4 24 | $411.3M | $63.3M | ||
| Q3 24 | $396.9M | $90.7M | ||
| Q2 24 | $360.1M | $78.5M | ||
| Q1 24 | $325.9M | $114.3M |
总债务APLSHPP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSHPP
| Q4 25 | $370.1M | $3.0B | ||
| Q3 25 | $401.2M | $3.2B | ||
| Q2 25 | $156.3M | $3.4B | ||
| Q1 25 | $164.2M | $2.8B | ||
| Q4 24 | $228.5M | $2.9B | ||
| Q3 24 | $237.1M | $3.0B | ||
| Q2 24 | $264.3M | $3.1B | ||
| Q1 24 | $266.7M | $3.2B |
总资产APLSHPP
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.1B | $7.8B | ||
| Q2 25 | $821.4M | $8.1B | ||
| Q1 25 | $807.3M | $8.0B | ||
| Q4 24 | $885.1M | $8.1B | ||
| Q3 24 | $901.9M | $8.3B | ||
| Q2 24 | $904.5M | $8.4B | ||
| Q1 24 | $831.9M | $8.3B |
负债/权益比APLSHPP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $121.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSHPP
| Q4 25 | $-14.2M | $121.0M | ||
| Q3 25 | $108.5M | $33.2M | ||
| Q2 25 | $4.4M | $-2.0M | ||
| Q1 25 | $-53.4M | $30.5M | ||
| Q4 24 | $19.4M | $164.7M | ||
| Q3 24 | $34.1M | $63.7M | ||
| Q2 24 | $-8.3M | $35.6M | ||
| Q1 24 | $-133.0M | $65.1M |
自由现金流APLSHPP
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSHPP
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSHPP
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSHPP
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HPP
| Core Office | $217.1M | 85% |
| Studio Segment | $21.8M | 9% |
| Ancillary Revenue | $20.2M | 8% |
| Chargebacks | $3.3M | 1% |
